A Study to Evaluate LY3154207 on the Brain of Healthy Participants

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Placebo; Drug: LY3154207

• Registration Number: NCT04258826
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-02-05
• Study First Submitted QC: 2020-02-05
• Study First Posted: 2020-02-06
• Study Start: 2021-01-15
• Primary Completion: 2022-01-28
• Study Completion: 2022-01-28
• Status Verified: 2022-02-15
• Last Update Submitted: 2022-02-21
• Last Update Posted: 2022-02-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

-Overtly healthy males and non-childbearing females, as determined through medical history and physical examination

Read More

Exclusion Criteria

• Have known or ongoing psychiatric disorders
• Have contraindications to magnetic resonance imaging (MRI)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo administered orally in one of two study periods.
LY3154207	LY3154207	LY3154207 administered orally in one of two study periods.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain	Day 1, Approximately Day 28	Mean Connectivity and Mean Component Weight Between LY3154207 and Placebo in the Dorsal Attention Network (DAN), Frontoparietal Network (FPN), and Executive Control Network (ECN).

Trial Locations

Locations (1)

Northwestern University; 🇺🇸 Chicago, Illinois, United States